Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Thalassemia Treatment Market Share

ID: MRFR//7123-HCR | 90 Pages | Author: Kinjoll Dey| April 2024

A thorough evaluation of the thalassemia treatment market is important to identify key players, remedy tendencies, and patient demographics. Understanding the various desires of patients, such as age companies, ailment severity, and genetic variations, allows for centered techniques to satisfy unique requirements. Differentiation through personalized remedy strategies is vital in the thalassemia treatment market. Tailoring remedies based on male or female patient traits, consisting of genetic mutations and iron overload stages, enhances remedy efficacy and units a logo aside in phrases of precision medicine. Offering complete patient help programs is a strategic pass. These programs can also consist of financial help, counseling services, and academic resources, fostering long-term relationships with patients and improving emblem loyalty.
Ensuring global accessibility to thalassemia treatments includes addressing affordability and regulatory concerns. Developing pricing trends that accommodate distinctive healthcare structures and participating with global regulatory bodies enables market growth and equitable affected persons to get the right of entry. Active participation in scientific trials and studies projects showcases a dedication to advancing thalassemia treatment options. Involvement in modern-day studies not only contributes to scientific know-how but additionally positions an emblem as a pacesetter in the pursuit of advanced healing procedures. Investing in academic tasks focused on healthcare specialists is critical. Providing training applications, workshops, and non-stop medical education possibilities guarantees that healthcare providers are well-informed about the modern-day improvements in thalassemia treatment, influencing treatment decisions.
Recognizing the role of telemedicine in contemporary healthcare, integrating thalassemia treatment with telehealth offerings is strategic. Offering faraway consultations, monitoring, and guide services enhances affected persons' accessibility, particularly for those in far-off or underserved areas. Ensuring regulatory compliance and retaining great standards in remedy protocols are non-negotiable. Adhering to global rules and acquiring vital certifications instills self-belief in sufferers and healthcare specialists, contributing to market credibility. Actively engaging in community outreach and helping affected person advocacy companies build a high-quality emblem image. Participation in occasions, sponsorships, and consciousness campaigns fosters a feeling of community and positions the logo as an associate in the fight against thalassemia.
With a developing cognizance of company responsibility, incorporating sustainability projects in production and operations can beautify an organization's photo. Practices consisting of environmentally friendly packaging or reducing the environmental impact of remedy production align with cutting-edge values. Developing crisis reaction plans and preparedness for unexpected occasions, together with supply chain disruptions or public fitness emergencies, guarantees continuity in providing thalassemia treatments. Proactive crisis control contributes to maintaining patient belief and market resilience.

Thalassemia Treatment Market Outlook

The Thalassemia Treatment Market is projected to reach USD 15.1 Billion by 2032 at 10.7% CAGR during the forecast period 2023-2032. Thalassemia, specifically the Beta- thalassemia disorder, is majorly caused by the mutation in the Hemoglobin Subunit Beta (HBB) gene. For instance, at least 5.2% of the world population and over 7% of pregnant women have a genetic mutation.

Thalassemia is an inherited blood disorder wherein the body makes an inadequate amount of hemoglobin. Hemoglobin disorders were initially prevalent in 60% of 229 countries, that potentially affected 75% of births, but are now sufficiently common in 71% of countries amongst 89% of births.

Thalassemia Treatment Market Influencers

Major companies are concentrating on mergers and acquisitions, new product developments, approvals, and regional expansions. For instance, in September 2019, Bluebird Bio, Inc. (US) has approved the first gene therapy for Beta-thalassemia. This gene therapy eliminates the need for blood transfusions in patients with β-thalassemia. Thus, major manufacturers are focusing on approvals in thalassemia treatment, which ultimately drives the growth of the Thalassemia Treatment Market.

Market Drivers

  • The rising incidence of thalassemia is expected to drive the growth of the market. Patients with insufficient hemoglobin suffer from thalassemia. For instance, thalassemia affects approximately 4.4 of every 10,000 live births throughout the world.

  • Increasing pipeline drugs in thalassemia is expected to drive the growth of the market. There are approximately 15 pipeline products under clinical trials for the treatment of thalassemia. For instance, in December 2016, Kiadis Pharma announced initiation of Phase I/II clinical trial with ATIR201 for thalassemia.

  • A rise in awareness regarding available treatment options for the treatment of thalassemia is expected to drive the growth of the Thalassemia Treatment Market.

  • The rise in demand for improved curative gene therapy is expected to drive the growth of the market.

Market Restraints

  • Stringent regulatory policies

  • High treatment costs

Thalassemia Treatment Market Segmentation

By Type

  • Alpha-thalassemia: Fastest growing segment. It is one of the most common autosomal recessive disorders. There is an increased incidence of the alpha-globin disorders in the US and other Western nations which eventually drives the growth of the thalassemia treatment market. However, about 5% of the world’s population is affected by alpha-thalassemia.

  • Beta Thalassemia: It is caused by reduced or no production of beta-globin subunits. About 1.5% of the global population is affected by Beta-thalassemia.

By Treatment

  • Blood Transfusions: The largest growing segment owing to the low risks involved due to careful blood screening. This treatment gives strong red blood cells along with normal hemoglobin. About 56,000 population have major thalassemia, wherein, at least 30,000 need regular blood transfusions. Thus, rising demand for blood transfusions is expected to drive the growth of the market.

  • Iron Chelation Therapy: This includes removing excess iron from the bloodstream. Iron chelator drugs such as desferrioxamine, deferiprone, and deferasirox are majorly used in this treatment.

  • Folic Acid Supplements: Folic acid is vitamin B that helps build strong red blood cells. These supplements are majorly consumed during and after pregnancy. However, 4% had started consuming after becoming pregnant. Thus, the increased use of folic acid is expected to drive the growth of this segment.

  • Gene therapy: Scientists are investigating genetic techniques to treat thalassemia. Gene therapy named Zynteglo was first launched by Bluebird Bio, Inc. (US) in September 2019.

  • Bone Marrow transplants: These transplants are not done very often as significant risks are involved but can be tried if no bone marrow matched donor is available. However, the patient will not need further blood transfusions if this transplantation is done. As a result, it would drive the Thalassemia Treatment Market growth in this segment.

By End-User

  • Hospitals & Clinics: Holds the largest market share owing to the increase in the number of hospital admissions for the treatment of thalassemia. Moreover, increasing occurrence of thalassemia is also expected to drive this segment.

  • Diagnostic laboratories: This segment holds significant market share owing to the increasing awareness regarding thalassemia treatment.

  • Others: This segment includes research laboratories, educational institutes, among others.

By Region

  • Americas: The largest growing regional Thalassemia Treatment Market owing to rising awareness about thalassemia and increasing government efforts to support gene therapy. However, Beta-thalassemia disorder is relatively rare in the US.

  • Europe: The introduction of gene therapy for the treatment of thalassemia is expected to boost the growth of market. For instance, in September 2019, Bluebird Bio, Inc. (US) has obtained approval for gene therapy that would remove the need for blood transfusions for people with blood disorder beta-thalassemia.

  • Asia-Pacific: The fastest-growing regional market in thalassemia treatment. Increasing investment in healthcare infrastructure is expected to drive the growth of the market in this region.

  • Middle East & Africa: Increasing adoption rate of blood transfusion treatment in countries such as Turkey and GCC would drive the demand for thalassemia treatment in this region.

Thalassemia Treatment Market Key Players

  • Novartis AG (Switzerland)

  • Bluebird Bio, Inc. (US)

  • Kiadis Pharma (Netherlands)


  • Sangamo Therapeutics (US)

  • Acceleron Pharma, Inc. (US)

  • Gamida Cell (Israel)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.